To appraise the clinical and cost effectiveness of:Isatuximab + carfilzomib + dexamethasone within its marketing authorisation for multiple myeloma
Status In progress
Process STA 2018
ID number 1620


Key events during the development of the guidance:

Date Update
05 September 2019 In progress, Referred 29 April 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance